Part of a new analysis from the ongoing Hopkins Lupus Cohort provides new knowledge that may help physicians make decisions about gradually reducing corticosteroid doses in people with lupus.
Jasvinder Singh, M.D., a prominent researcher in rheumatic disease, has been awarded a $1.5 million, three year grant from the Patient-Centered Outcomes Research Institute for a decision aid to help doctors and their African-American and Hispanic lupus patients with kidney disease choose the best treatment for each individual patient.
At the 2014 American College of Rheumatology Annual Scientific Meeting, Dr. Sara K. Tedesch presented her study on the relationship between lupus activity prior to getting pregnant and during pregnancy. The Lupus Foundation of America conducted a Q&A with Dr. Tedeschi about her study.
Lupus-related kidney inflammation (lupus nephritis) is one of the most common and serious complications of lupus. However, a new study demonstrates that an understudied inflammation pathway in lupus may bring researchers closer to developing a novel blood-based test that could predict the progression of kidney failure.
At a scientific symposium in San Francisco last month, some of the country’s foremost experts on lupus shared their insights about the current state of lupus clinical trial design. Read more.
Insights from the 2014 American College of Rheumatology Reproductive Health Summit
Lupus Foundation of America supported study demonstrates that blocking STAT5 reduces the production of CD154 by half.
Adolescent-onset lupus has worse prognosis and increased risk of lupus-related kidney disease and death.